Benitec Biopharma announced last week that it has selected the Duke Clinical Research Unit as a site for its upcoming phase I/II trial for the expressed RNAi-based hepatitis C infection treatment TT-034.
The trial is designed to evaluate single escalating doses of the drug in patients with chronic HCV genotype I infection who have failed previous treatment, Benitec said.
It is expected to enroll 14 patients in five sequential dose cohorts, with the possibility of additional cohorts added to confirm study findings. Endpoints include safety, as well as serum viral load reduction and hepatocyte transduction levels.
Patient enrollment is expected to begin in the second half of the year.